NCT03460977 2026-04-16
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
Pfizer
AstraZeneca
Hansoh BioMedical R&D Company
Eli Lilly and Company
Jiangsu HengRui Medicine Co., Ltd.